8-K: Seer Reports Q3 2025 Results: Revenue Up, Net Loss Narrows

Seer, Inc. announced its third quarter 2025 financial results, reporting a 2% revenue increase to $4.1 million and a reduced net loss of $18.2 million, alongside strong instrument shipments and a robust cash position.

Summary

• Generated revenue of $4.1 million for the third quarter of 2025, a 2% increase from $4.0 million in the corresponding prior year period.
• Achieved a record quarter for third-party publications and preprints, with more than 60 total to date.
• Ended the quarter with approximately $251.2 million of cash, cash equivalents, and investments.
• Shipped nearly three times as many instruments in the first nine months of 2025 as in all of 2024.
• Gross profit was $2.1 million and gross margin was 51% for the third quarter of 2025.
• Operating expenses decreased by 18% to $21.5 million, compared to $26.3 million in the prior year period, primarily due to reductions in stock-based compensation, business expenses, and allocated costs.
• Net loss was $18.2 million for the third quarter of 2025, compared to $21.3 million for the corresponding prior year period.
• Reaffirmed full year 2025 revenue guidance in the range of $17 million to $18 million, representing 24% growth at the midpoint over full year 2024.

Sentiment

Score: 7

Explanation: While the company is still operating at a loss, the significant reduction in net loss, decrease in operating expenses, strong cash position, and positive operational metrics like instrument shipments and third-party publications indicate solid progress and execution against strategic goals. The maintained full-year guidance also provides stability.

Positives

• Revenue increased by 2% year-over-year to $4.1 million for the third quarter of 2025.
• Net loss significantly narrowed to $18.2 million from $21.3 million in the prior year period, indicating improved financial performance.
• Operating expenses decreased by 18% year-over-year, driven by reductions in stock-based compensation, business expenses, and allocated costs.
• Maintained a strong cash position with approximately $251.2 million in cash, cash equivalents, and investments as of September 30, 2025.
• Achieved a record quarter for third-party publications and preprints, with over 60 total to date, validating the Proteograph technology's performance.
• Experienced robust demand and utilization for the Proteograph ONE workflow, leading to strong instrument shipments.
• Shipped nearly three times as many instruments in the first nine months of 2025 as in all of 2024, demonstrating growing adoption.
• Reaffirmed full year 2025 revenue guidance, projecting 24% growth at the midpoint over full year 2024.

Negatives

• The company continues to report a net loss of $18.2 million for the quarter, indicating ongoing unprofitability.
• Product revenue slightly decreased to $2.756 million in Q3 2025 from $2.915 million in Q3 2024.
• Interest income decreased to $2.765 million from $4.082 million in the prior year period.
• Loss on equity method investment increased to $1.419 million from $0.861 million in the prior year period.
• Total assets decreased to $308.608 million as of September 30, 2025, from $366.597 million as of December 31, 2024.
• Total stockholders' equity decreased to $271.814 million from $327.569 million over the same period.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those expressed or implied.
• Specific risks are described more fully in Seer's other filings with the Securities and Exchange Commission (SEC) and other documents that Seer subsequently files with the SEC from time to time.

Future Outlook

Seer continues to expect full year 2025 revenue to be in the range of $17 million to $18 million, representing growth of 24% at the midpoint over full year 2024. The company anticipates continued adoption of its technology and expansion of the reach and impact of the Proteograph Product Suite.

Management Comments

• "In Q3, we saw robust demand and utilization for our recently launched Proteograph ONE workflow, resulting in another strong quarter for instrument shipments." Omid Farokhzad, Chair and CEO of Seer.
• "Notably, we have shipped nearly three times as many instruments in the first nine months of this year as we did in all of 2024." Omid Farokhzad, Chair and CEO of Seer.
• "We also saw a record number of third-party publications demonstrating the value of the Proteograph and further validating its performance across a range of applications." Omid Farokhzad, Chair and CEO of Seer.
• "Together, these achievements highlight the growing adoption of our technology and reinforce our leadership in enabling deep, unbiased proteomics at scale." Omid Farokhzad, Chair and CEO of Seer.
• "I’m proud of our team’s execution as we advance the reach and impact of the Proteograph Product Suite." Omid Farokhzad, Chair and CEO of Seer.

Industry Context

Seer operates in the proteomics industry, aiming to provide deep, unbiased proteomic insights at scale. The reported record number of third-party publications and strong instrument shipments suggest growing validation and adoption of their Proteograph Product Suite, indicating a positive trend within the broader life sciences research and biotechnology sector for advanced proteomic technologies. The company positions itself as a pioneer and leader in overcoming challenges of traditional proteomic methods, reinforcing its market presence.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks for direct industry comparison.

Related Party Transactions

• Service revenue for the third quarter of 2025 included $300 thousand of related party revenue.
• Cost of related party revenue was $85 thousand for the third quarter of 2025.
• Related party receivables were $300 thousand as of September 30, 2025.

Stakeholder Impact

• Shareholders: The narrowed net loss and maintained revenue guidance could be viewed positively, while the strong cash position provides financial stability. However, continued operational losses may still be a concern.
• Customers: Robust demand and utilization for the Proteograph ONE workflow and increased instrument shipments indicate strong customer adoption and satisfaction with the company's products.
• Employees: Reduced operating expenses, including stock-based compensation, might impact employee incentives or future hiring, though specific details are not provided.

Next Steps

• Host a conference call on November 6, 2025, at 1:30 pm Pacific Time / 4:30 pm Eastern Time to discuss the third quarter 2025 financial results.
• Continue to advance the reach and impact of the Proteograph Product Suite.
• Continue to file with the SEC as required by law.

Key Dates

Recommendation

While Seer demonstrated positive operational momentum with increased instrument shipments, growing adoption of its technology, and a significant reduction in net loss, it continues to operate at a loss. The revenue growth, while positive, is modest at 2% year-over-year for the quarter. The strong cash position provides a buffer, but sustained profitability remains a key challenge. Investors should hold to observe if the company can translate its operational successes into consistent revenue growth and a clear path to profitability in subsequent quarters.

Keywords

Proteomics, Proteograph, SEER, Financial Results, Q3 2025, Life Sciences, Biotechnology, Instruments, Consumables, Research Use